Olaparib + Chemotherapy for Advanced Ovarian Cancer
Trial Summary
Do I need to stop taking my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot be on any systemic anticancer chemotherapy or radiotherapy within two weeks before starting the study treatment.
What data supports the effectiveness of the drug combination of Olaparib, Carboplatin, and Paclitaxel for advanced ovarian cancer?
Research shows that the combination of Olaparib and Carboplatin is tolerable and provides clinical benefits in certain patients with heavily pretreated ovarian cancer, even if they are resistant to platinum-based treatments. Additionally, Olaparib has shown effectiveness as a maintenance therapy in relapsed ovarian cancer, helping to delay disease progression.12345
Is the combination of Olaparib and chemotherapy safe for treating advanced ovarian cancer?
What makes the drug combination of Olaparib, Carboplatin, and Paclitaxel unique for treating advanced ovarian cancer?
This drug combination is unique because it combines Olaparib, a PARP inhibitor that targets cancer cells with specific genetic mutations, with Carboplatin and Paclitaxel, which are chemotherapy drugs that work by damaging the DNA of cancer cells. This combination aims to enhance the effectiveness of treatment by using different mechanisms to control the disease.135910
What is the purpose of this trial?
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
Research Team
Amit Oza, MD
Principal Investigator
Princess Margaret Hospital, Canada
Jane Robertson, BSc, MBCHB, MD
Principal Investigator
AstraZeneca
Eligibility Criteria
This trial is for patients with advanced ovarian cancer who have had no more than three prior platinum treatments and were progression-free for at least six months after the last one. They must have at least one measurable lesion and be diagnosed with serous ovarian cancer. Those with recent chemotherapy, radiotherapy, or hypersensitivity to related medications cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive olaparib in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone
Follow-up
Participants are monitored for progression-free survival and overall survival
Long-term follow-up
Participants are contacted every 12 weeks to assess survival status
Treatment Details
Interventions
- Carboplatin
- Olaparib
- Paclitaxel
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology